27677368|t|Corn oil intake favorably impacts lipoprotein cholesterol, apolipoprotein and lipoprotein particle levels compared with extra-virgin olive oil
27677368|a|Corn oil (CO) and extra-virgin olive oil (EVOO) are rich sources of unsaturated fatty acids (UFA), but UFA profiles differ among oils, which may affect lipoprotein levels. The objective of this study was to assess the effects of CO versus EVOO intake on fasting lipoprotein and subfraction cholesterol levels, apolipoprotein (apo) A1, apo B, and low-density lipoprotein particle concentrations in men and women. As part of a weight maintenance diet, men and women were provided with food items prepared with 54 g per day of CO or EVOO (21-day treatment, 21-day washout) in a randomized, double-blind, controlled-feeding, crossover trial. Fasting lipoprotein cholesterol and related variables were determined with density gradient ultracentrifugation. Among the 54 completers, CO reduced total cholesterol, low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apo B and LDL particle concentration to a greater extent compared with EVOO intake. Changes in LDL-C and VLDL-C contributed to the larger reduction in non-HDL-C with CO compared with EVOO intake (-0.39 mmol/l vs -0.04 mmol/l; P<0.001). The larger reduction in LDL-C by CO intake was attributable to changes (P<0.05) caused by CO vs EVOO in large LDL1+2-C (-0.22 mmol/l) and intermediate-density lipoprotein cholesterol (-0.12 mmol/l). HDL-C responses did not differ between treatments, but apo A1 increased more with EVOO compared with CO intake (4.6 versus 0.7 mg/dl, respectively, P=0.016). CO intake reduced atherogenic lipoprotein cholesterol and particle concentrations to a larger extent than did EVOO, which may have implications for cardiovascular disease risk.
27677368	0	15	Corn oil intake	T109,T168	C0010029
27677368	16	25	favorably	T080	C3640814
27677368	26	33	impacts	T080	C4049986
27677368	34	57	lipoprotein cholesterol	T116,T123	C0065055
27677368	59	73	apolipoprotein	T059	C0523476
27677368	78	89	lipoprotein	T059	C0523753
27677368	99	105	levels	T080	C0441889
27677368	106	114	compared	T052	C1707455
27677368	120	142	extra-virgin olive oil	T109,T168	C0069449
27677368	143	151	Corn oil	T109,T168	C0010029
27677368	153	155	CO	T109,T168	C0010029
27677368	161	183	extra-virgin olive oil	T109,T168	C0069449
27677368	185	189	EVOO	T109,T168	C0069449
27677368	200	210	sources of	T033	C0449416
27677368	211	234	unsaturated fatty acids	T109	C0015690
27677368	236	239	UFA	T109	C0015690
27677368	246	249	UFA	T109	C0015690
27677368	272	276	oils	T109	C0028908
27677368	295	313	lipoprotein levels	T059	C0523753
27677368	319	328	objective	T170	C0018017
27677368	350	356	assess	T058	C0184514
27677368	372	374	CO	T109,T168	C0010029
27677368	382	386	EVOO	T109,T168	C0069449
27677368	397	404	fasting	T033	C0015663
27677368	405	416	lipoprotein	T059	C0523753
27677368	433	451	cholesterol levels	T059	C0201950
27677368	453	476	apolipoprotein (apo) A1	T059	C0853934
27677368	478	483	apo B	T059	C0523509
27677368	489	512	low-density lipoprotein	T059	C0202116
27677368	522	536	concentrations	T081	C1446561
27677368	540	553	men and women	UnknownType	C0682069
27677368	568	591	weight maintenance diet	T061	C0920298
27677368	593	606	men and women	UnknownType	C0682069
27677368	626	636	food items	T168	C0016452
27677368	667	669	CO	T109,T168	C0010029
27677368	673	677	EVOO	T109,T168	C0069449
27677368	686	695	treatment	T169	C1522326
27677368	718	728	randomized	T062	C0034656
27677368	730	742	double-blind	T062	C0013072
27677368	744	762	controlled-feeding	T062	C0015746
27677368	764	779	crossover trial	T062	C0150097
27677368	781	788	Fasting	T033	C0015663
27677368	789	812	lipoprotein cholesterol	T116,T123	C0065055
27677368	840	850	determined	T080	C0521095
27677368	856	892	density gradient ultracentrifugation	T059	C0007704
27677368	919	921	CO	T109,T168	C0010029
27677368	922	929	reduced	T080	C0392756
27677368	930	947	total cholesterol	T109	C0543421
27677368	949	984	low-density lipoprotein cholesterol	T059	C0202117
27677368	986	991	LDL-C	T059	C0202117
27677368	994	1034	very low-density lipoprotein cholesterol	T059	C0523560
27677368	1036	1042	VLDL-C	T059	C0523560
27677368	1045	1085	non-high-density lipoprotein cholesterol	T059	C1535899
27677368	1087	1096	non-HDL-C	T059	C1535899
27677368	1099	1104	apo B	T059	C0523509
27677368	1109	1112	LDL	T059	C0202116
27677368	1122	1135	concentration	T081	C1446561
27677368	1156	1164	compared	T052	C1707455
27677368	1170	1174	EVOO	T109,T168	C0069449
27677368	1194	1199	LDL-C	T059	C0202117
27677368	1204	1210	VLDL-C	T059	C0523560
27677368	1237	1246	reduction	T080	C0392756
27677368	1250	1259	non-HDL-C	T059	C1535899
27677368	1265	1267	CO	T109,T168	C0010029
27677368	1268	1276	compared	T052	C1707455
27677368	1282	1286	EVOO	T109,T168	C0069449
27677368	1346	1355	reduction	T080	C0392756
27677368	1359	1364	LDL-C	T059	C0202117
27677368	1368	1370	CO	T109,T168	C0010029
27677368	1425	1427	CO	T109,T168	C0010029
27677368	1431	1435	EVOO	T109,T168	C0069449
27677368	1445	1453	LDL1+2-C	T059	C0202116
27677368	1473	1517	intermediate-density lipoprotein cholesterol	T059	C0523559
27677368	1534	1539	HDL-C	T059	C0392885
27677368	1573	1583	treatments	T169	C1522326
27677368	1589	1595	apo A1	T059	C0853934
27677368	1596	1605	increased	T081	C0205217
27677368	1616	1620	EVOO	T109,T168	C0069449
27677368	1621	1629	compared	T052	C1707455
27677368	1635	1637	CO	T109,T168	C0010029
27677368	1692	1694	CO	T109,T168	C0010029
27677368	1702	1709	reduced	T080	C0392756
27677368	1710	1733	atherogenic lipoprotein	T033	C1531719
27677368	1722	1745	lipoprotein cholesterol	T116,T123	C0065055
27677368	1759	1773	concentrations	T081	C1446561
27677368	1786	1792	extent	T082	C0439792
27677368	1802	1806	EVOO	T109,T168	C0069449
27677368	1840	1867	cardiovascular disease risk	T033	C0847284